SEC Form 4 · accession 0001654954-17-003028
Cellular Biomedicine Group, Inc. · CBMG
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Yihong Yao
Officer — Chief Scientific Officer
Period of report
Mar 3, 2017
Accepted (ET)
Apr 3, 2017 · 7:36 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001378624
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 27, 2017 | A | 26,500 | $0.00 | A | 26,500 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy) (2014 Plan)F2 | $12.40 | Mar 3, 2017 | A | 26,500 | A | — | Mar 3, 2027 | Common Stock | 26,500 | 26,500 | D |
Explanation of responses
- F1The Reporting Person was granted 26,500 restricted stock units ("RSUs") (Grant No. LTIP RSU G4) under the Cellular Biomedicine Group, Inc. 2014 Stock Incentive Plan, which RSUs vest over a period of four years according to the following schedule: 1/48th per month, with the first installment vested on March 27, 2017.
- F2This option (Grant No. 14-327) vests over a period of four years according to the following schedule: 1/48th per month, with the first installment vested on March 27, 2017.